Related Experiment Video

Updated: Aug 29, 2025

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

440

Xiaotan Sanjie Decoction Inhibits Gastric Cancer Cell Proliferation, Migration, and Invasion through lncRNA-ATB and

Zhe Zhou1,2,3, Jiabin Chen1,2,3, Mingqian Li2,3

  • 1The Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou 310053, Zhejiang Province, China.

Biomed Research International
|September 5, 2022
PubMed

Insights

Xiaotan Sanjie decoction (XTSJ) effectively inhibits gastric cancer (GC) cell proliferation and metastasis. XTSJ downregulates lncRNA-ATB and EMT markers, offering a potential treatment for GC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Traditional Chinese Medicine

Background:

  • Gastric cancer (GC) remains a significant global health challenge.
  • Dysregulation of long non-coding RNAs (lncRNAs), such as lncRNA-ATB, is implicated in GC progression.
  • Novel therapeutic strategies targeting molecular pathways are urgently needed.

Purpose of the Study:

  • To investigate the inhibitory effects of Xiaotan Sanjie decoction (XTSJ) on gastric cancer (GC) proliferation and metastasis.
  • To explore the role of XTSJ in regulating lncRNA-ATB expression in GC cells.
  • To elucidate the molecular mechanisms underlying XTSJ's anti-cancer effects.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) and Western blot were employed to assess lncRNA-ATB and related protein expression.
  • Cell Counting Kit-8 (CCK8), EdU assays, and flow cytometry were used to evaluate cell proliferation and apoptosis.
  • Transwell and wound healing assays were performed to determine the impact of XTSJ on cell migration and invasion.
  • In vivo tumor growth inhibition was assessed.

Main Results:

  • XTSJ demonstrated a dose-dependent inhibition of HGC-27 cell proliferation and metastasis.
  • XTSJ downregulated lncRNA-ATB, Vimentin, and N-cadherin while upregulating miR-200a and E-cadherin.
  • XTSJ modulated apoptosis-related proteins (Caspase 3, Caspase 9, Bax, Bcl-2) and inhibited epithelial-mesenchymal transition (EMT) signaling pathways.
  • XTSJ suppressed tumor growth in vivo.

Conclusions:

  • XTSJ exhibits significant anti-proliferative and anti-metastatic effects on gastric cancer cells.
  • The mechanism involves the regulation of lncRNA-ATB and miR-200a, impacting EMT and Bcl-2 signaling pathways.
  • XTSJ presents a promising therapeutic candidate for gastric cancer, particularly in cases with elevated lncRNA-ATB levels.

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.0K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K